Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
about
Therapy of human papillomavirus-related diseaseHPV clearance and the neglected role of stochasticityPhase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.The role of sexual behavior and human papillomavirus persistence in predicting repeated infections with new human papillomavirus types.Association between toll-like receptor expression and human papillomavirus type 16 persistence.Human papillomavirus concordance in heterosexual couples.Human papillomavirus disease and vaccines in adolescents.Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope HotspotExpression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated responseDevelopment of a novel liquid bead array human papillomavirus genotyping assay (PGMY-LX) and comparison with linear array for continuity in longitudinal cohort studiesBiomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: markers of immune response?Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:CImmunotherapy of human papilloma virus induced diseaseRedetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.Updating the natural history of human papillomavirus and anogenital cancersCandida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine.T cell susceptibility to HIV influences outcome of opportunistic infections.Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence.The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infectionImmunologic treatments for precancerous lesions and uterine cervical cancer.Recent advances in understanding and preventing human papillomavirus-related disease.Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy.Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota.Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy.Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice.Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.
P2860
Q27007473-C191632D-A582-4376-B383-B8ABBD54B4A7Q28652424-A2C5E1A1-FE1A-4AC6-9DDC-E7109B1BD0F0Q33783092-98B18415-F113-455D-B27E-593D235D3253Q34059901-B62A00FD-7EB2-40C6-8B1E-BAE2EA13C214Q34187046-8548A63A-C360-4E04-A0B7-C829ED1D84F9Q34257094-818AC1A8-05FF-4970-B24D-47BA2891AA11Q34675079-B50C04EC-4059-4855-A921-4126A0577EA4Q35049821-5FCA2721-F35C-44DC-BFCF-589489B78C0AQ35077577-B3351F97-AB26-485F-90C5-8FB5C4BB7EDDQ35164128-EB6D162B-4F18-4040-883F-CA4829177A16Q35193233-FEC196C2-73E4-4625-9E22-599ABE3A089FQ35870615-2AC20DB0-C184-4309-8291-F262F8103C7FQ36315857-14F2E0D6-CFB9-4623-983B-F9A810A26E2BQ36541008-32D88960-20F2-4F80-8212-0BCEAA87B0F6Q36974917-B5E3FA3C-BF1D-4881-87A8-877308B5E28EQ36979148-36F68186-F2D7-4EFD-8B3E-43104967DE84Q37377608-77255DB1-0637-4FCD-818F-CAE8776E26C2Q37382387-6D0126B7-606D-4714-A32A-8C47077F639EQ37604535-9888D941-7BCE-4169-AA27-8EF7DABBAED9Q37668390-80649885-326A-42E9-AFF1-315C378EB095Q37703113-CE7CEED3-15BB-4161-B650-40D1AE66CC0BQ37709706-1A731CED-2FB2-47B4-8669-B917239E92D9Q38036688-1F27DC9B-89B0-48B2-899F-4EBD7457D8FEQ40306609-743510C8-C903-4167-A6B7-BF443A18AD44Q40359015-D55EA401-DA24-4AA7-8B19-F07E35BD0B68Q40533645-0C87F376-C5D8-402A-AD28-8E811E19F5A9Q42243834-B19476F8-EBEE-4250-AD10-E4CEF504F581Q47224779-358F25E1-E675-41D2-AD9D-8245669F9E7AQ50134597-33FE7CA7-8CA5-4B62-9B54-7A08C12DE9ACQ51008590-C74E2217-FD11-4A77-ACF9-2CB09ED9EE88
P2860
Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cell-mediated immune responses ...... uman papillomavirus infection.
@en
Cell-mediated immune responses ...... uman papillomavirus infection.
@nl
type
label
Cell-mediated immune responses ...... uman papillomavirus infection.
@en
Cell-mediated immune responses ...... uman papillomavirus infection.
@nl
prefLabel
Cell-mediated immune responses ...... uman papillomavirus infection.
@en
Cell-mediated immune responses ...... uman papillomavirus infection.
@nl
P2093
P2860
P1476
Cell-mediated immune responses ...... uman papillomavirus infection.
@en
P2093
Anna-Barbara Moscicki
Mayumi Nakagawa
Sepideh Farhat
P2860
P304
P356
10.1111/IGC.0B013E3181A388C4
P577
2009-05-01T00:00:00Z